A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats
Hummel, C.W., Geiser, A.G., Bryant, H.U., Cohen, I.R., Dally, R.D., Fong, K.C., Frank, S.A., Hinklin, R., Jones, S.A., Lewis, G., McCann, D.J., Rudman, D.G., Shepherd, T.A., Tian, H., Wallace, O.B., Wang, Y., Dodge, J.A.(2005) J Med Chem 48: 6772-6775
- PubMed: 16250633 
- DOI: https://doi.org/10.1021/jm050723z
- Primary Citation of Related Structures:  
2AYR - PubMed Abstract: 
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors alpha and beta (ERalpha and ERbeta, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation.
Organizational Affiliation: 
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.